{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"}],"units":"Participants"}],"description":"Response is defined by the Response Evaluation Criteria in the protocol, namely the earliest point where all relevant tests (i.e. lab tests, physical exam, radiology results) are consistent with complete response (CR) or partial response (PR). CR or PR must be confirmed for at least 4 weeks. Complete response: No evidence of leukemic cells by routine H/E stains of the peripheral blood and bone marrow. Partial response:neutrophils \\>/= 1,500/micrograms/L or 50% improvement over baseline without growth factors for at least 4 weeks.","groups":[{"description":"30 micrograms/kg intravenous over 30 minutes every other day (QOD) on days 1, 3, 5, of a 4 week cycle (at least 26 days) for a maximum of 16 cycles or until they become ineligible.","id":"OG000","title":"BL22 Immunotherapy"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"2/14/2009 till 6/24/2010","title":"Number of Months to Response to Treatment","type":"PRIMARY","unitOfMeasure":"Months"}